Invacare Corporation announces the appointment of Petra Danielsohn-Weil, PhD, to its Board of Directors.
Her appointment increases the number of Invacare directors to eight, seven of whom are considered independent directors.
Danielsohn-Weil has more than 30 years of experience in the medical and pharmaceutical fields in Europe.
Most recently, from 2014 until her retirement in August 2017, she was the regional president for Pfizer Essential Health – Europe. From 2000 until her retirement, she served in various general management, regional and global business unit executive roles in Europe and the United States for Pfizer, according to a media release from Invacare Corp.
Prior to that, she served in various commercial and strategic leadership roles in Europe and the US for Warner-Lambert from 1988 until its acquisition by Pfizer in 2000. She serves as a board member of NovaMedica LLP, a pharmaceutical company and a portfolio company of Rusnano JSC Corporation.
Danielsohn-Weil holds an undergraduate degree in Educational Psychology, a Master’s Degree in Chemistry and Biology, and a PhD in Biology from the University of Munster in Germany.
“We are pleased to welcome Petra to the Invacare Board of Directors. Petra has a wealth of experience in the European market in commercial development, business integration, R&D, sales, digital marketing, and implementing long-term strategic plans in a complex environment. With our significant operations in Europe, her background and unique experience in emerging markets in the European biotech space will be invaluable as we continue our journey,” says Matthew E. Monaghan, chairman, president and chief executive officer of Invacare Corp, in the release.
“I look forward to joining the Invacare Board of Directors and working with Matt Monaghan, Dr Martin Harris, lead director, and my colleagues on the Board, as we continue through the company’s transformation,” Danielsohn-Weil shares.
[Source(s): Invacare Corp, Business Wire]